Stork, Lidia
Ellenberger, David
Ruprecht, Klemens
Reindl, Markus
Beißbarth, Tim
Friede, Tim
Kümpfel, Tania
Gerdes, Lisa A.
Gloth, Mareike
Liman, Thomas
Paul, Friedemann
Brück, Wolfgang
Metz, Imke http://orcid.org/0000-0002-6571-7630
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung
Article History
Received: 24 October 2019
Revised: 20 December 2019
Accepted: 22 December 2019
First Online: 16 January 2020
Compliance with ethical standards
:
: L. Stork has nothing to disclose.D. Ellenberger has nothing to disclose.K. Ruprecht was supported by the German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis) and has received research support from Novartis and Merck Serono as well as speaking fees and travel grants from Guthy Jackson Charitable Foundation, Bayer Healthcare, Biogen Idec, Merck Serono, sanofi-aventis/Genzyme, Teva Pharmaceuticals, Roche and Novartis.M. Reindl was supported by research grants from the Austrian Science Funds (FWF), Austrian Science Promotion Agency (FFG) and the Austrian Multiple Sclerosis Research Society. The University Hospital and Medical University of Innsbruck (Austria; M.R.) receives payments for antibody assays (MOG, AQP4, and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Lübeck, Germany).T. Beißbarth has nothing to disclose.T. Friede has received personal fees for consultancies (including data monitoring committees) in the past three years from Bayer, BiosenseWebster, Boehringer Ingelheim, Cardialysis, CSL Behring, DaiichiSankyo, Enanta, Feldmann Patent Attorneys, Fresenius Kabi, Galapagos, IQVIA, Janssen, Mediconomics, Novartis, Penumbra, Roche, SGS, Vifor; all outside the submitted work.T. Kümpfel has received travel expenses and speaker honoraria from Bayer Healthcare, Teva Pharma, Merck, Novartis Pharma, Sanofi-Aventis/Genzyme, CLB Behring, Roche Pharma and Biogen as well as grant support from Bayer-Schering AG, Novartis and Chugai Pharma.LA. Gerdes has received travel expenses and speaker honoraria from Merck, Sanofi-Aventis/Genzyme and Roche Pharma.M. Gloth has nothing to disclose.F. Paul serves on the scientific advisory board for Novartis; received speaker honoraria and travel funding from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; is an academic editor for PLoS ONE; is an associate editor for Neurology Neuroimmunology and Neuroinflammation; consulted for SanofiGenzyme, Biogen Idec, MedImmune, Shire, and Alexion; and received research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, German Research Council, Werth Stiftung of the City of Cologne, German Ministry of Education and Research, Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation.W. Brück is supported from the German Ministry of Education and Research (BMBF “German Competence Network Multiple Sclerosis (KKNMS)”). Dr. Brück has received, outside the submitted work, honoraria for lectures by Bayer Vital, Biogen, Merck Serono, Teva Pharma, Genzyme, Sanofi-Aventis, Celgene and Novartis and is a member of scientific advisory boards for Teva Pharma, Biogen, Novartis and Genzyme. He received funding for research projects by Teva Pharma, Biogen, Novartis and Genzyme. Dr. Brück serves on the editorial boards of Neuropathology and Applied Neurobiology, Multiple Sclerosis International and Therapeutic Advances in Neurological Disorders.I. Metz reports grants from German Ministry for Education and Research (BMBF, "German Competence Network Multiple Sclerosis", Pattern MS/NMO), during the conduct of the study; personal fees from BiogenIdec, Bayer Healthcare, TEVA, Serono, Novartis, Genzyme, Roche, grants from BiogenIdec, Genzyme, Novartis, grants from N-RENNT 2 (Niedersachsen Research Network on Neuroinfectiology), outside the submitted work.